FBRX Key Statistics, Chart & Performance
The current stock price of FBRX is 27.87 USD. In the past month the price increased by 46.07%. In the past year, price increased by 21.6%.
FBRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.34 | 406.46B | ||
| AMGN | AMGEN INC | 15.22 | 179.28B | ||
| GILD | GILEAD SCIENCES INC | 15.23 | 154.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.66 | 117.45B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.44 | 82.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 785.47 | 52.92B | ||
| INSM | INSMED INC | N/A | 37.94B | ||
| NTRA | NATERA INC | N/A | 32.26B | ||
| BIIB | BIOGEN INC | 10.58 | 25.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.22 | 21.84B | ||
| INCY | INCYTE CORP | 15.59 | 19.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About FBRX
Company Profile
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 16 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Company Info
FORTE BIOSCIENCES INC
3060 Pegasus Park Drive, Building 6
Dallas TEXAS 90502 US
CEO: Paul Wagner
Employees: 16
Phone: 13106186994
FORTE BIOSCIENCES INC / FBRX FAQ
Can you describe the business of FORTE BIOSCIENCES INC?
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The company is headquartered in Dallas, Texas and currently employs 16 full-time employees. The company went IPO on 2017-04-13. The company is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The firm's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
What is the stock price of FORTE BIOSCIENCES INC today?
The current stock price of FBRX is 27.87 USD. The price increased by 1.57% in the last trading session.
Does FBRX stock pay dividends?
FBRX does not pay a dividend.
How is the ChartMill rating for FORTE BIOSCIENCES INC?
FBRX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about FORTE BIOSCIENCES INC (FBRX) stock?
12 analysts have analysed FBRX and the average price target is 55.9 USD. This implies a price increase of 100.56% is expected in the next year compared to the current price of 27.87.
Would investing in FORTE BIOSCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FBRX.
Can you provide the upcoming earnings date for FORTE BIOSCIENCES INC?
FORTE BIOSCIENCES INC (FBRX) will report earnings on 2026-03-26, after the market close.
FBRX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to FBRX. When comparing the yearly performance of all stocks, FBRX is one of the better performing stocks in the market, outperforming 94.73% of all stocks.
FBRX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FBRX. No worries on liquidiy or solvency for FBRX as it has an excellent financial health rating, but there are worries on the profitability.
FBRX Financial Highlights
Over the last trailing twelve months FBRX reported a non-GAAP Earnings per Share(EPS) of -5.77. The EPS increased by 71.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.29% | ||
| ROE | -61.53% | ||
| Debt/Equity | 0 |
FBRX Forecast & Estimates
12 analysts have analysed FBRX and the average price target is 55.9 USD. This implies a price increase of 100.56% is expected in the next year compared to the current price of 27.87.